November 13 from 6:00 pm – 8:00 pm PST
Supported By: Boehringer Ingelheim Pharmaceuticals, Inc.
Join expert faculty Ara Dikranian, MD and Toby Maher, MD, PhD as they provide an overview of the OFEV pivotal safety and efficacy data and provide a case study example to underscore the importance of identifying appropriate patients for treatment with OFEV.
This program is developed and offered by Boehringer Ingelheim Pharmaceuticals, Inc. This is not an official program of the American College of Rheumatology. This is a non-CME event and does not qualify for CME, CE, or MOC credit. Presentation content has been reviewed for consistency with FDA guidelines. Speakers receive fair market value compensation for this presentation. Aspects of this program may be reportable under the Physicians Payment Sunshine Act. Pursuant to the PhRMA (Pharmaceutical Research and Manufacturers of America) Code on Interactions with Healthcare Professionals, attendance at this promotional program is limited to healthcare professionals. Attendance by healthcare professionals’ spouses or guests is not permitted.
Toby M. Maher, MD, PhD
Keck Medicine of USC
Professor of Clinical Medicine
Los Angeles, California
Ara H. Dikranian, MD
Cabrillo Center for Rheumatic Disease
San Diego, California